Pasi A. Jänne
Pasi A. Jänne is translational thoracic medical oncologist at the Dana Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. He is also the co-leader of the Dana Farber/Harvard Cancer Center lung cancer program and the Scientific co-director of the Belfer Institute for Applied Cancer Sciences. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a Masters Degree in clinical investigation from Harvard University. He has been a member of IASLC since 2000.
Dr Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interest centers around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being on one of the co-discoverers of EGFR mutations, and his work has led to the development of several clinical trials. Dr. Jänne has received several awards for his research including from Uniting Against Lung Cancer, American Lung Association and the Bonnie J. Addario Lung Cancer Foundation. In 2008 he was elected as a member to the American Society of Clinical Investigation. He is also the recipient of 2010 American Association of Cancer Research Richard and Hinda Rosenthal Memorial Award and a member of the 2010 AACR Team Science Award.
He will serve on the IASLC Board of Directors for four years, starting at the WCLC in 2013.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.